Aduro Biotech (ADRO) Reports Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604
Tweet Send to a Friend
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced data from preclinical studies with ADU-1604, the company’s humanized anti-CTLA-4 monoclonal antibody ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
